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In a screening program to discover therapeutic drugs
for heart diseases, we identified BTZO-1, a 1,3-
benzothiazin-4-one derivative, which activated
antioxidant response element (ARE)-mediated gene
expression and suppressed oxidative stress-
induced cardiomyocyte apoptosis in vitro. An active
BTZO-1 derivative for ARE-activation protected
heart tissue during ischemia/reperfusion injury in
rats. Macrophage migration inhibitory factor (MIF),
which is known to protect cells from oxidative insult,
was identified as a specific BTZO-1-binding protein.
BTZO-1 binds to MIF with a Kd of 68.6 nM, and its
binding required the intact N-terminal Pro1. MIF, in
the presence of BTZO-1, activated the glutathione
S-transferase Ya subunit (GST Ya) gene ARE,
whereas reduction of cellular MIF protein levels by
siRNA suppressed BTZO-1-induced GST Ya expres-
sion. These results suggest that BTZO-1 activates
the GST Ya gene ARE by interacting with MIF.
INTRODUCTION
Heart disease, including heart failure and myocardial infarction
(MI), is associated with high mortality in modern Western socie-
ties (Cleland et al., 2001). A key predictor for the development of
heart failure is the presence of left ventricular hypertrophy, and
the progressive deterioration of the hypertrophied left ventricle
(LV) may be related to progressive loss of cardiomyocytes, at
least in part, via apoptosis (van Empel et al., 2005). Apoptosis
has also been detected in heart tissue at all stages of MI (Abbate
et al., 2006). Thus, apoptosis may be responsible for a significant
amount of cardiomyocyte death during the acute ischemic
stage, as well as for the progressive loss of surviving cells during
the subacute and chronic stages. Cardiomyocytes are terminally
differentiated and lose their proliferative capacity (Akazawa and
Komuro, 2003). Therefore, loss of cardiomyocytes results in
a permanent reduction in the number of functioning units in the
myocardium. Inhibitors of cardiomyocyte apoptosis could be
novel therapeutic agents for cardiovascular diseases.1282 Chemistry & Biology 17, 1282–1294, December 22, 2010 ª2010Here, we describe the identification of 2-pyridin-2-yl-4H-1,3-
benzothiazin-4-one (BTZO-1), which suppressed cardiomyocyte
apoptosis in vitro probably via activation of antioxidant response
element (ARE)-mediated gene expression. ARE is a cis-acting
DNA regulatory element involved in the induction of multiple
cytoprotective factors, including glutathione S-transferases
(GSTs), heme oxygenase-1 (HO-1), and g-glutamylcysteine
synthetase (g-GCS) (Nguyen et al., 2003b; Chen and Kunsch,
2004; Kaspar et al., 2009), and its activation is considered
amechanism of critical importance for cellular protection against
oxidative stress in mammalian cells (Chen and Kunsch, 2004; De
Vries et al., 2008). BTZO-2, an active BTZO-1 derivative with
a better ADME profile, protected heart tissue during ischemia/
reperfusion injury in rats. BTZO-1 appears to be a promising lead
compound for the discovery of therapeutics for heart diseases.
Wealso report the identification ofmacrophagemigration inhib-
itory factor (MIF), a ubiquitous protein, as a specific BTZO-1-
binding protein.MIF has been reported tobe releasedby ischemic
heart tissue and to activate the cardioprotective AMP-activated
protein kinase (AMPK) pathway (Miller et al., 2008). Several
studies have suggested that MIF is a critical upstream regulator
of the innate and acquired immune response (Calandra and
Roger, 2003). In addition, MIF has been found to have a variety
of biological functions such as the regulation of cytokine secre-
tion, counter-regulation of glucocorticoids in inflammation, inhi-
bition of oxidative stress-induced cell death, and activation of
components of the mitogen-activated protein kinase and Jun-
activation domain-binding protein-1 (Jab-1) pathway; however,
its precise function in the majority of cells is not known (Calandra
and Roger, 2003; Lolis and Bucala, 2003; Bach et al., 2008).
Our results suggest that BTZO-1 activates the rat glutathione
S-transferase Ya subunit (GST Ya) gene ARE via binding to MIF.
RESULTS
Identification of BTZO-1
To discover novel therapeutic drugs for heart diseases, we es-
tablished an in vitro screening assay for inhibitors of cardiomyo-
cyte apoptosis using human leukemia inhibitory factor (hLIF) as
a control (Fujio et al., 1997; Sheng et al., 1997). Cell death was
induced in the primary culture of neonatal rat cardiomyocytes
by serum deprivation for 4 days and then cell viability was as-
sessed using 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-
(2,4-disulfophenyl)-2H-tetrazolium monosodium salt, WST-8,Elsevier Ltd All rights reserved
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Figure 1. BTZO-1 Suppresses Serum Deprivation or DOX-Induced Cell Death in the Primary Culture of Neonatal Rat Cardiomyocytes
(A) Inhibitory activity of hLIF against serum deprivation-induced cell death in cultured neonatal rat cardiomyocytes. Cell death was induced in cardiomyocytes by
culturing in serum-deprived medium for 4 days. Cell viability was determined by the WST-8 assay. Results shown are mean ± SD, n = 8.
(B) Chemical structure of BTZO-1.
(C) Inhibitory activity of BTZO-1 against serum deprivation-induced cardiomyocyte death. Results shown are mean ± SD, n = 3.
(D) Suppression of serum deprivation-induced internucleosomal cleavage of genomic DNA in cardiomyocytes by BTZO-1. Cardiomyocytes were maintained in
the presence or absence of 0.37 mMBTZO-1 in serum-freemedia for 3 days and then genomic DNAwas isolated and analyzed by electrophoresis on agarose gel.
Lane 1 shows the molecular weight maker; lane 2 the control; and lane 3, 0.37 mM of BTZO-1.
(E) Inhibitory activity of hLIF or BTZO-1 against DOX-induced death of cardiomyocytes. Cardiomyocytes were pretreated with samples for 3 hr in serum-free
medium and then cell death was induced by treatment with 200 nM of DOX for 18 hr. Cell viability was evaluated by the WST-8 assay. Results shown are
mean ± SD, n = 6.
(F) Chemical structure of BTZO-1 derivatives.
(G) Inhibitory activity of BTZO-1 derivatives against serum deprivation-induced cardiomyocyte death. Results shown are mean ± SD, n = 3. See also Figure S1.
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MIF Regulates ARE Activation(WST-8 assay). The hLIF dose dependently increased the
number of live cells (Figure 1A). Using this assay, BTZO-1 (Fig-
ure 1B) was identified from our chemical library. BTZO-1 dose
dependently suppressed serum deprivation-induced cardio-
myocyte death; the minimum effective concentration (MEC1.5),
defined as the concentration of a sample necessary to give
a 50% increase in cell viability, was 16 nM (Figure 1C).
To confirm that the observed cell deaths were secondary to
apoptosis, we evaluated cells for the presence of internucleoso-
mal cleavage by monitoring for DNA laddering, a hallmark of
apoptosis, on agarose gels (Sheng et al., 1997). Cardiomyocytes
caused internucleosomal cleavage of the genomic DNA after
culturing for 3 days in serum-free medium, and BTZO-1 at
0.37 mM suppressed this internucleosomal cleavage (Figure 1D).
These results suggest that the observed cell death is, at least in
part, secondary to apoptosis and that BTZO-1 suppressed car-
diomyocyte apoptosis. BTZO-1, as well as LIF, also suppressedChemistry & Biology 17, 1282–129doxorubicin (DOX)-induced cell death in cardiomyocytes (Wang
et al., 1998) (Figure 1E).
Serum deprivation or stimulation with DOX has been reported
to cause oxidative stress; therefore, we suspected that
BTZO-1 is an antioxidant. However, BTZO-1 antioxidant activity,
measured by 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scav-
enging activity, was at least 100 times lower than that of trolox,
a vitamin E derivative with potent antioxidant properties (Mickle
and Weisel, 1993; Abe et al., 1998). On the other hand, cardio-
myocyte apoptosis inhibitory activity of BTZO-1 was about
10,000 times more potent than trolox; the MEC1.5 of trolox was
160 mM (see Figures S1A and S1B available online). Thus,
BTZO-1 appeared to have a mode of action different from being
an antioxidant.
Examination of the structure-activity relationships for BTZO-1
derivatives revealed that introduction of a methyl group at the
eight position (BTZO-3), reduction of the C = N bond (BTZO-4),4, December 22, 2010 ª2010 Elsevier Ltd All rights reserved 1283
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Figure 2. BTZO-1 Activates ARE and Protects Heart Tissue from Ischemia-Reperfusion Injury
(A) Nucleotide sequence of rat GST Ya gene ARE. The core ARE sequence is indicated by the nucleotides in boldface type.
(B) Reporter gene assays showing the effects of BTZO-1 derivatives on ARE activity. H9c2 cells transiently transfected with either pGL3-ARE-Luc or pGL3-
mARE-Luc reporter plasmids were treated with BTZO-1 derivatives for 24 hr. Results shown are mean ± SD, n = 4.
(C) BTZO-1 upregulatesmRNA levels of GSTYa andHO-1 in cardiomyocytes. Cells were treatedwith the indicated concentrations of BTZO-1 derivatives for 24 hr
in serum-free medium. Messenger RNA levels of GST Ya and HO-1 were measured by real-time quantitative PCR. Results shown are mean ± SD, n = 3.
(D) BTZO-1 upregulates protein levels of GST Ya and HO-1 in cardiomyocytes. Protein extracts were analyzed by western blot analysis with anti-GST Ya (top),
anti-HO-1 (middle), or anti-b-actin (bottom) antibodies. b-actin was used as a control.
(E) Effects of BTZO-2 on infarct size following LAD occlusion reperfusion (25 min to 24 hr) in anaesthetized rats. Area at risk is expressed as percentage of the LV.
Infarct size is expressed as the percentage of the area at risk. Treatment with BTZO-2 (10mg/kg, i.p.) 1 hr prior to LAD occlusion, and 2 and 8 hr after reperfusion,
significantly reduced the infarct size. Results shown are mean ± SEM; control, n = 13; BTZO-2, n = 10. **p < 0.01 versus control. See also Table S1.
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MIF Regulates ARE Activationor replacement of the phenyl ring of 1,3-benzothiazin-4-one with
a pyridine ring (BTZO-5) resulted in a sharp decrease in
apoptosis inhibition activity, whereas introduction of a side chain
to the pyridine ring, such as a carboxyethyl group (BTZO-2),
retained activity; the MEC1.5 of BTZO-2 was 39 nM, whereas
those of BTZO-3, BTZO-4, and BTZO-5 were >1000 nM (Figures
1F and 1G).
BTZO-1 Activates ARE-Mediated Gene Expression
Total RNAwas recovered from the primary culture of cardiomyo-
cytes cultured in the presence or absence of 0.37 mM of BTZO-1
for 21 hr in a serum-free medium and then the global gene
expression pattern was investigated using the Affimetrix Gene-
Chip rat genome U34A array, which contains approximately
7000 known genes. Transcription of 89 known genes was upre-
gulated with more than a 2-fold change, and 17 of these were
genes possibly induced via ARE (Table S1). ARE activation is
important for cellular protection against oxidative stress (Nguyen
et al., 2003b; Chen and Kunsch, 2004); therefore, we hypothe-
sized that BTZO-1 inhibits cardiomyocyte apoptosis via induc-
tion of cytoprotective factors through ARE activation.
As support for this hypothesis, the effects of BTZO-1 and its
derivatives on the induction of ARE-mediated gene expression
were investigated using a luciferase reporter assay in H9c2 cells,1284 Chemistry & Biology 17, 1282–1294, December 22, 2010 ª2010a cell line derived from rat cardiac myoblasts. We constructed
a pGL3-ARE-Luc reporter plasmid that expressed luciferase
under the control of rat GST Ya ARE (Rushmore et al., 1991; Ven-
ugopal and Jaiswal, 1998; Dhakshinamoorthy and Jaiswal,
2000). As a control, we also constructed a pGL3-mARE-Luc
reporter plasmid in which a point mutation (A/G) was intro-
duced into the core sequence (TGACAAAGC) of rat GST Ya
ARE that almost completely abolished its activity (Figure 2A)
(Rushmore et al., 1991). When H9c2 cells transfected with
pGL3-ARE-Luc, but not pGL3-mARE-Luc, were treated with
BTZO-1, luciferase activity was induced in a dose-dependent
manner (Figure 2B). Thus, the incremental values of luciferase
activity in cells transfected with pGL3-ARE-Luc are ARE depen-
dent. Active BTZO-1 derivatives for apoptosis inhibition (BTZO-1
and BTZO-2) induced luciferase activity in a dose-dependent
manner, whereas inactive derivatives (BTZO-3, BTZO-4, and
BTZO-5) had little or no effect on pGL3-ARE-Luc transfected
H9c2 cells (Figure 2B). The MEC2.0 of BTZO-1, BTZO-2,
BTZO-3, BTZO-4, and BTZO-5 for ARE activation, which was
determined to be the concentration of a compound necessary
to double luciferase activity, was 0.82, 2.3, >10, >10, and
>10 mM, respectively (Table 1).
BTZO-1 derivatives showed similar structure-activity relation-
ships in the induction of ARE-regulated cytoprotective genes,Elsevier Ltd All rights reserved
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MIF Regulates ARE Activationsuch as GST Ya and HO-1 in the primary culture of neonatal rat
cardiomyocytes. Only active derivatives for apoptosis inhibition
remarkably increased both GST Ya and HO-1 mRNA levels (Fig-
ure 2C); BTZO-1 andBTZO-2, but not BTZO-3, increased protein
levels of GST Ya and HO-1 in cardiomyocytes (Figure 2D). These
results suggest that BTZO-1 inhibits cardiomyocyte apoptosis
via activation of ARE-mediated gene expression.
BTZO-2 Reduces Infarct Size Caused by Myocardial
Ischemia/Reperfusion in Rats
The effect of BTZO-2, a BTZO-1 analog with a better ADME
profile, on infarct size following ischemia/reperfusion was inves-
tigated by measuring the infarct size 24 hr after reperfusion. The
mean values for the area at risk were 46% ± 3% (vehicle) and
48% ± 2% (BTZO-2), respectively (Figure 2E). In rats that
received vehicle, left anterior descending coronary artery (LAD)
occlusion and reperfusion resulted in an infarct size of 43% of
the area at risk (control). When compared to vehicle, intraperito-
neal administration (10mg/kg) of BTZO-2 1 hr prior to LAD occlu-
sion and 2 and 8 hr after reperfusion gave an approximately 45%
reduction in infarct size (p = 0.0013) (Figure 2E).
Identification of MIF as a Possible BTZO-1 Target
Protein
To clarify the molecular mechanisms involved in ARE activation
by BTZO-1, we tried to identify possible target protein(s) for
BTZO-1 by drug-affinity chromatography (Kimura et al., 2010).
Five BTZO-1 derivatives with a carboxy-ethoxypropyl side chain
(BTZO-7, BTZO-8, BTZO-9, BTZO-10, and BTZO-11) were
prepared for affinity chromatography. BTZO-7 and BTZO-8 are
structurally similar to BTZO-1, whereas BTZO-9, BTZO-10, and
BTZO-11 are structurally similar to BTZO-3 (BTZO-6), BTZO-4,
and BTZO-5, respectively. BTZO-7 and BTZO-8 had potent
ARE activation/apoptosis inhibition activity equivalent to that of
BTZO-1. In contrast BTZO-9, BTZO-10, and BTZO-11 up to
10 mMdid not activate ARE and up to 1 mMdid not suppress car-
diomyocyte apoptosis, presumably due to introduction of
a methyl group at the eight position, reduction of the C = N
bond, or replacement of the phenyl ring of the 1,3-benzothia-
zin-4-one with a pyridine ring, respectively (Table 1).
Protein extracts of rat heart were applied to the two positive
columns (BTZO-7 and BTZO-8 columns) and a negative column
(BTZO-9 column). After washing the columnswith binding buffer,
bound proteins were eluted with 1 M NaCl buffer. By analyzing
each fraction by SDS-PAGE followed by silver staining,
a common binding protein with a molecular mass of approxi-
mately 12.5 kDa (indicated by arrows) was identified from the
eluted fractions of the two positive columns, but not from the
negative BTZO-9-column (Figure 3A). Amino acid sequence
analysis revealed that the 12.5 kDa protein was MIF.
Next, we analyzed the binding of BTZO-1 derivatives to puri-
fied recombinant rat MIF (rMIF). rMIF was diluted with binding
buffer and then was applied to the two positive columns
(BTZO-7 and BTZO-8 columns) and the three negative columns
(BTZO-9, BTZO-10, and BTZO-11 columns). After washing the
columns with binding buffer, bound protein was eluted with an
elution buffer containing 1M NaCl. Analysis of each collected
fraction by SDS-PAGE followed by silver staining revealed that
rMIF was retained on the positive BTZO-7 and BTZO-8 columns,Chemistry & Biology 17, 1282–129but not on the negative BTZO-9, BTZO-10, and BTZO-11
columns (Figure 3B). These results suggest that BTZO-1 deriva-
tives active for ARE activation/apoptosis inhibition directly
interact with rMIF.
We used a surface plasmon resonance (SPR) biosensor tech-
nique to further identify possible target protein(s) of BTZO-1 (Lo-
pez et al., 2003). In this experiment, aminohexylaminocarbonyl
variants of BTZO-1 derivatives (BTZO-12 and BTZO-13) were
used. BTZO-12 and BTZO-13 are structurally similar to BTZO-1
and BTZO-3, respectively; BTZO-12 retained ARE-activation
activity equivalent to that of BTZO-1, whereas BTZO-13 was
less potent due to introduction of a methyl group to the eight
position of the 1,3-benzothiazin-4-one (Table 1). BTZO-12 and
BTZO-13 were each immobilized with a surface density of 655
resonance units (RU) and 816 RU, respectively, on the activated
sensor chip CM5 (BTZO-12-type sensor chip and BTZO-13-type
sensor chip). The BTZO-12-type sensor chip, but not the BTZO-
13-type sensor chip, gave a strong binding signal when protein
extract from rat heart was analyzed (Figure 3C). To analyze the
bound proteins on the BTZO-12-type sensor chip, we took
advantage of a micro-elution procedure available on BIACORE
3000 instruments fitted with a Surface Prep Unit (SPU) (Lopez
et al., 2003). Analysis of the recovered fractions by silver staining
showed an intense band of low molecular weight (below
16.5 kDa) together with several faint bands, and this low molec-
ular weight protein was confirmed to be MIF by western blot
analysis (Figure 3D). Furthermore, the BTZO-12-type sensor
chip, but not the BTZO-13-type sensor chip, displayed a strong,
direct interaction with rMIF (Figure 3E). These data are in good
agreement with the results of the experiments using drug-
coupled columns (Figures 3A and 3B). MIF may be a target
protein of BTZO-1.BTZO-1-hMIF Interaction Requires an Intact
N-Terminal Pro1
MIF has been predicted to have at least two distinct functional
domains: a tautomerase catalytic domain and a thiol-mediated
oxidoreductase catalytic domain. Curiously, MIF tautomerase
non-physiological substrates like D-dopachrome by its hydro-
phobic cavity at the N terminus, and the N-terminal proline
(Pro1) is involved in the catalytic function (Bendrat et al., 1997;
Lubetsky et al., 1999). The cysteine thiol-mediated oxidoreduc-
tase catalytic domain of MIF was reported to have a CXXC motif
(Kleemann et al., 1998).
To identify the region of MIF that interacts with BTZO-1, we
prepared a purified recombinant human MIF protein (hMIF) and
five variant forms: substitution of Pro1 with serine (hMIF-P1S)
or glycine (hMIF-P1G) (Bendrat et al., 1997; Lubetsky et al.,
1999); substitution of the second cysteine in the CXXC motif
with serine (hMIF-C59S) (Kleemann et al., 1998); addition of
a 30 amino acid peptide with a 6His-tag to the N terminus (His-
hMIF); or an eight amino acid peptide with a 6His-tag to the
C terminus (hMIF-His) (Figure 4A). The D-dopachrome tautomer-
ase activity of these MIF proteins was spectrophotometrically
determined: mutation or blockage of Pro1 (hMIF-P1S, hMIF-
P1G, and His-hMIF) resulted in a substantial reduction in cata-
lytic activity, addition of a peptide to the C terminus (hMIF-His)
partially reduced the activity, and substitution of cysteine in the4, December 22, 2010 ª2010 Elsevier Ltd All rights reserved 1285
Table 1. Chemical Structure and Activities of BTZO-1 and Its Derivatives
Chemical Structure
ARE Activation,
MEC2.0 (mM)
Apoptosis Inhibition,
MEC1.5 (nM)
Tautomerase Inhibition, %
Inhibition at 30 mM
BTZO-1 0.82 16 13
BTZO-2 2.3 39 14
BTZO-3 >10 >1000 6
BTZO-4 >10 >1000 3
BTZO-5 >10 >1000 5
BTZO-6 >10 >1000 ND
BTZO-7 2.2 53 ND
BTZO-8 1.6 39 ND
BTZO-9 >10 >1000 ND
BTZO-10 >10 >1000 ND
BTZO-11 >10 >1000 ND
BTZO-12 1.1 ND ND
Chemistry & Biology
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Table 1. Continued
Chemical Structure
ARE Activation,
MEC2.0 (mM)
Apoptosis Inhibition,
MEC1.5 (nM)
Tautomerase Inhibition, %
Inhibition at 30 mM
BTZO-13 >10 ND ND
BTZO-14 0.80 39 12
MEC2.0 (mM) for ARE activation was set as the concentration of each compound necessary to double the luciferase activity in pGL3-ARE-Luc reporter
plasmid-transfected H9c2 cells. MEC1.5 for inhibition of serum deprivation-induced apoptosis was set as the concentration of each sample necessary
to give a 50% increase in the viability of cardiomyocytes. Inhibition of rMIF tautomerase activity was measured using L-dopachrome carboxy-methyl
ester as a substrate. ND, not determined.
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MIF Regulates ARE ActivationCXXC motif (hMIF-C59S) had little effect on enzymatic activity
(Figure 4B; Figure S2A).
The consequence of modulating the interaction with BTZO-1
was evaluated by SPR analysis using the BTZO-12-type sensor
chip (BTZO-12 was immobilized with a surface density of 655
RU). N-terminal derivatives (His-hMIF, hMIF-P1S, and hMIF-
P1G) resulted in a drastic decrease in interaction, whereas
substitution of cysteine in the CXXC motif (hMIF-C59S) orDC
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Figure 4. BTZO-1 Binds to MIF with a Kd of 68.6 nM
(A) Schematic representation of hMIF and its mutants (hMIF-P1S, hMIF-P1G, hMIF-C59S, His-hMIF, hMIF-His) employed in the SPR analysis using the BTZO-12-
type sensor chip.
(B) Tautomerase activity of hMIF and various mutants using 0.1 mM D-dopachrome as a substrate. Absorbance at 475 nm was measured after 5 min. Results
shown are mean ± SD, n = 3.
(C) Evaluation of specific binding of hMIF and various mutants to the BTZO-12-type sensor chip.
(D) Effects of BTZO-1 on the tautomerase activity of rMIF. Purified L-dopachrome carboxy-methyl ester was used as a substrate. Results shown are mean ± SD,
n = 4.
(E) SPAmeasurement of selective [3H]-BTZO-1 binding to hMIF-His. The 6His-tagged rat GST Ya and rat VILIP3 were used as control proteins. Results shown are
mean, n = 2.
(F) Analysis of saturation isotherms showing a single saturable high-affinity binding site (Kd = 68.6 nM). Results shown are means, n = 3.
Chemistry & Biology
MIF Regulates ARE Activation
1288 Chemistry & Biology 17, 1282–1294, December 22, 2010 ª2010 Elsevier Ltd All rights reserved
Chemistry & Biology
MIF Regulates ARE Activationvelocity of rMIF with L-dopachrome carboxy-methyl ester during
the initial 30 s was 268 mmol/min/mg MIF (Figure S2B). BTZO-1
partially inhibited the tautomerase reaction (Figure 4D and Table
1). Note that the binding affinity of BTZO-1 to rMIF was lower at
pH 6.0 than at pH 7.3, as assessed by SPR with BTZO-12
(Figure S2C).BTZO-1 Interacts with hMIF with a Kd of 68.6 nM
A scintillation proximity assay (SPA) was used to measure the
affinity of BTZO-1 to MIF (Kimura et al., 2010). hMIF-His was im-
mobilized on YSi (2–5 mm) copper His-tag SPA beads. Binding of
the radioligand [3H]-BTZO-1 to hMIF-His led to excitation of the
scintillant contained in the SPA beads, and the concomitant light
emission was measured by beta counter. Specific interactions
between hMIF-His and [3H]-BTZO-1 were detected; however,
when other 6His-tagged proteins, such as GST Ya and visinin-
like protein 3 (VILIP3), were used instead of hMIF-His, binding
of [3H]-BTZO-1 was not detected, which suggests that BTZO-1
interacts specifically with MIF (Figure 4E). Specific binding was
defined as the total binding minus nonspecific binding; nonspe-
cific binding of [3H]-BTZO-1 to the YSi (2–5 mm) copper His-tag
SPA beads was estimated in the absence of hMIF-His. Analysis
of the saturation isotherms gave a single saturable high-affinity
binding site (Kd = 68.6 nM) (Figure 4F). The Kd of BTZO-1 with
the 6-His-tagged rat MIF protein (rMIF-His) was 157 nM (Fig-
ure S2D). The Kd of BTZO-1 with hMIF, measured by SPR anal-
ysis using the BTZO-12-type sensor chip, was 88 nM
(Figure S2E).Crystallography of the hMIF-BTZO-14 Complex
To determine the structural basis for the interaction between
BTZO-1 derivatives and MIF, BTZO-14, a BTZO-1 derivative
with higher solubility, was co-crystallized with hMIF. BTZO-14
was comparable to BTZO-1 for ARE activation/apoptosis inhibi-
tion (Table 1) and for binding affinity to hMIF (Figure 4G). The
hMIF-BTZO-14 complex was crystallized as a trimer as previ-
ously reported for uncomplexed rat and hMIF (Suzuki et al.,
1996; Sun et al., 1996a, 1996b). BTZO-14 bound to the
N-terminal Pro1 of each hMIF subunit in the trimer. The carbon
atom at the two position of the 1,3-benzothiazin-4-one ring is
positioned at a distance of approximately 3.1 A˚ from the amino
terminus of Pro1, within the sum of the van der Waals radii for
carbon and nitrogen atoms (Figures 4H and 4I; Figure S2F).
BTZO-14 also bound to the area between the symmetry-related
MIF molecules in the crystal structure. This BTZO-14 was posi-
tioned between aromatic side chains of Trp108 and Tyr36 from
two adjacent MIF molecules and formed a hydrogen bond
between the carbonyl oxygen of BTZO-14 and Gln35 (Figures
4H and 4J; Figure S2G).(G) Sensorgram showing binding of BTZO-1 or BTZO-14 to immobilized hMIF on
(H) The electron density map shows a well-ordered BTZO-14 in complex with theM
of the trimer, the BTZO-14 thiazinone ring is bound in a skewed conformation. B
(BTZO-14 in purple).
(I) BTZO-14 bound to the vicinity of Pro1 in each MIF monomer. BTZO-14 is show
cule in the trimer is shown in cyan. Hydrogen bonds and other distinct interactio
(J) BTZO-14 was also positioned between aromatic ring side chains of Trp108 a
Chemistry & Biology 17, 1282–129MIF Induces GST Ya Expression and Suppresses Nitric
Oxide-Induced Cardiomyocyte Death
Recent observations that MIF-deficient cells are sensitized to
nitric oxide (NO)-induced apoptosis (Mitchell et al., 2002), MIF
protects cells from oxidative stress-induced apoptosis (Hudson
et al., 1999; Mitchell et al., 2002; Nguyen et al., 2003a), MIF
enhances cellular levels of glutathione whose synthesis depends
on ARE-regulated g-GCS (Nguyen et al., 2003a), and MIF
induces expression of ARE-regulated GST (Takahashi et al.,
2001) suggested a potential regulation of ARE by MIF. Interest-
ingly, MIF could mediate biological activity through either a clas-
sical receptor-mediated pathway (Leng et al., 2003; Shi et al.,
2006) or a nonclassical endocytic pathway (Calandra and Roger,
2003; Kleemann et al., 2000). Thus, we first evaluated whether
rMIF inhibits NO-induced cell death and activates transcription
of ARE-regulated genes in cardiomyocytes. Cell death was
induced with 30 mM of a NO generator, NOR3, in the presence
or absence of rMIF, and then cell viability was measured by
the WST-8 assay. rMIF significantly suppressed NO-induced
cardiomyocyte death (Figure 5A).
Next, cardiomyocytes were stimulated with rMIF in the pres-
ence or absence of 10 mM NOR3 and then the mRNA levels of
representative ARE-regulated genes, GST Ya and HO-1, were
measured. rMIF stimulation slightly induced GST Ya and HO-1
expression, and NO co-stimulation promoted the rMIF-induced
expression of these genes (Figure 5B). rMIF might protect cells
from NO-induced death by upregulation of ARE-mediated
gene expression. These results, together with the potent and
specific binding of BTZO-1 to MIF, prompted us to investigate
the molecular mechanisms by which BTZO-1 might induce
ARE activation by binding to MIF.
BTZO-1 Promotes MIF-Induced GST Ya ARE Activation
H9c2 cells were stimulated with rMIF in the presence or absence
of BTZO-1 and then ARE activationwas evaluated by a luciferase
reporter assay. BTZO-3, a BTZO-1 derivative with a lower
binding affinity to MIF due to introduction of a methyl group to
the eight position of the 1,3-benzothiazin-4-one (Figures 3B
and 3E, and Table 1), was used as a negative control. Stimulation
of pGL3-ARE-Luc transfected H9c2 cells with rMIF in the pres-
ence of 1 mM BTZO-1 resulted in a dose-dependent induction
of luciferase activity (not observed with pGL3-mARE-Luc trans-
fected cells), whereas stimulation with rMIF and 1 mM BTZO-3
slightly, and with rMIF alone scarcely induced ARE-mediated
luciferase activity (Figure 5C). Furthermore, co-stimulation of
H9c2 cells with BTZO-1, but not BTZO-3, promoted rMIF induc-
tion of GST Ya and HO-1 mRNA (Figure 5D). These results
suggest that MIF activates ARE in the presence of some ligand.
Oxygen-free radicals have been implicated in ARE activation;
however, BTZO-1 at 10 mM did not cause protein oxidationa sensor chip CM5 using a SPR biosensor.
IF monomer (green); however, in the other MIFmonomers (cyan andmagenta)
TZO-14 also bound to the area between the symmetry-related MIF molecules
n in yellow, the MIF molecule is highlighted in green, and the neighboring mole-
ns are indicated by red-dashed lines.
nd Tyr36 from both two adjacent MIF molecules. See also Figure S2.
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Figure 5. BTZO-1 Promotes rMIF-Induced ARE Activation
(A) rMIF suppresses NO-induced cardiomyocyte death in vitro (***p % 0.001). Cells were pretreated with the indicated concentrations of rMIF for 3.5 hr and
then were treated with 30 mM of NOR3 for 19 hr in serum-free medium. Cell viability was evaluated by the WST-8 assay. Results shown are mean ± SD,
n = 4. #p% 0.025.
(B) rMIF induces GST Ya and HO-1 expression in cardiomyocytes. Cells were stimulated with various concentrations of rMIF in the presence or absence of 10 mM
of NOR3 for 3hr (HO-1) or 6 hr (GST Ya). Messenger RNA levels of GSTYa andHO-1weremeasured by real-time quantitative PCR. Results shown aremean ± SD,
n = 3. #p% 0.025.
(C) BTZO-1, but not BTZO-3, promotes the rMIF-induced ARE activation in H9c2 cells. Cells transiently transfected with either pGL3-ARE-Luc or pGL3-mARE-
Luc reporter plasmid were treated with the indicated concentrations of rMIF in the presence or absence of 1 mMBTZO-1 or BTZO-3 for 24 hr. Results shown are
mean ± SD, n = 4. #p% 0.025.
(D) BTZO-1, but not BTZO-3, co-stimulation promoted rMIF-induced GST Ya and HO-1 induction in H9c2 cells. Cells were stimulated with the indicated concen-
tration of rMIF and 3 mM of BTZO-1 derivatives for 6 hr (HO-1) or 24 hr (GST Ya). Messenger RNA levels of GST Ya and HO-1 were measured by real-time quan-
titative PCR. Results shown are mean ± SD, n = 3. #p% 0.025. See also Figure S3.
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MIF Regulates ARE Activation(Figure S3A). To confirm the direct interaction between BTZO-1
and MIF in H9c2 cells, cells were treated with 30 mM of BTZO-1
for 6 hr and then tautomerase activity in the cell lysate was
measured. BTZO-1 pretreatment caused an approximately
20% decrease in enzyme activity (Figure S3B), which suggests
that there is a direct interaction between BTZO-1 and MIF in
H9c2 cells.
Reduction in Cellular MIF Levels Decreases
BTZO-1-Induced GST Ya mRNA Expression
We next investigated the effects of reducing the cellular MIF
protein level on BTZO-1-induced ARE activation by lowering
the MIF mRNA level with small interfering RNA (siRNA). We opti-
mized the conditions for MIF siRNA transfection and cell culture
by measuring MIF mRNA levels by real-time PCR analysis and
both cellular and medium MIF protein levels by MIF ELISA to
attain about 80%, 50%, and 75% reductions of these levels in
H9c2 cells, respectively (Figures 6A and 6B). Under these condi-
tions, we could not further transfect pGL3-ARE-Luc; thus, we as-
sessed ARE activation by measuring GST Ya and HO-1 mRNA
levels. Induction of GST Ya mRNA expression with 3 mM of1290 Chemistry & Biology 17, 1282–1294, December 22, 2010 ª2010BTZO-1 decreased in the MIF-reduced H9c2 cells, whereas
the addition of rMIF to the culture medium restored GST Ya
induction (Figures 6C and 6D). HO-1 mRNA showed a similar
pattern. These results suggest that BTZO-1 activates ARE-medi-
ated gene expression via binding to MIF.
Interaction of Several Known ARE-Activating Agents
and ISO-1 with MIF
The binding of several known ARE-activators, such as tert-butyl-
hydroquinone (t-BHQ), Hemin, 15-deoxy-delta-12,14-prosta-
glandin J2 (15d-PGJ2), and L-sulforaphane (SFN) (Nguyen
et al., 2003b), and ISO-1, a MIF tautomerase inhibitor (Lubetsky
et al., 2002), to MIF was measured by [3H]-BTZO-1/rMIF-His
SPA, which measured the competitive inhibition of [3H]-BTZO-1
binding to rMIF-His. IC50 values for BTZO-1, t-BHQ, Hemin,
15d-PGJ2, SFN, and ISO-1 were 0.071, 1.1, 34, 3.6, 25, and
>100 mM, respectively. Interestingly, ISO-1 did not activate
ARE at concentrations up to 30 mM. Hemin, 15d-PGJ2, SFN,
and ISO-1 also inhibited MIF tautomerase activity (Table S2).
Some of the known ARE activators might activate ARE via
binding to MIF.Elsevier Ltd All rights reserved
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Figure 6. Effects of Reducing the Cellular MIF Protein Level on the BTZO-1-Induced GST Ya and HO-1 Gene Expression in H9c2 Cells
H9c2 cells transfected with control siRNA (control siRNA), or siRNAs directed against rMIF (MIF siRNA) were treated with 3 mM BTZO-1 with or without 0.8 mM
rMIF for 24 hr.
(A) Messenger RNA levels of MIF were measured by real-time quantitative PCR. Results shown are mean ± SD, n = 3.
(B) Protein levels of MIF in the cell lysate (left) and culture media (right) were measured by ELISA. Results shown are mean ± SD, n = 3. ND, not determined.
(C) Messenger RNA levels of GST Ya and HO-1 were measured by real-time quantitative PCR. Results shown are mean ± SD, n = 3.
(D) Messenger RNA levels of GST Ya and HO-1 induced by 3 mM of BTZO-1 in H9c2 cells treated with control siRNA, MIF siRNA, or MIF siRNA plus rMIF. Values
were obtained from the data shown in (C). Results shown are mean ± SD, n = 3. *p% 0.05. See also Table S2.
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Cardiomyocyte apoptosis has been hypothesized to be a factor
in the initial cause and progression of heart failure. Here, we
show that BTZO-1 induced ARE-mediated expression of cyto-
protective genes and suppressed cardiomyocyte apoptosis
in vitro. BTZO-2, an active BTZO-1 derivative, showed potent
cytoprotection against myocardial ischemia/reperfusion injury
in rats. Pharmacological activation of endogenous cytoprotec-
tive proteins through activation of ARE may serve as a novel
strategy for the treatment of heart diseases.
MIF was identified as a target protein for BTZO-1 by drug-
affinity chromatography. MIF has been reported to protect cells
from oxidative stress-induced cell death (Hudson et al., 1999;
Mitchell et al., 2002; Nguyen et al., 2003a). We showed that
MIF treatment rescued cardiomyocytes from NO-induced cell
death and induced ARE-regulated GST Ya and HO-1 gene
expression in vitro. Thus, MIF seemed to be a reasonable target
protein for BTZO-1. Further analysis revealed that BTZO-1 deriv-Chemistry & Biology 17, 1282–129atives capable of GST Ya ARE activation selectively bound to
MIF, BTZO-1 promoted MIF-induced GST Ya ARE activation,
and BTZO-1-induced GST Ya induction was suppressed by
a reduction in cellular MIF levels. These results suggest that
MIF regulates the activation of GST Ya ARE and that BTZO-1,
via binding to MIF, acts as an activator of MIF.
ARE activation by MIF seems to require a ligand because NO
treatment upregulatedMIF-inducedGSTYa andHO-1 induction,
and BTZO-1, but not BTZO-3, co-stimulation upregulated MIF-
induced GST Ya ARE activation and GST Ya and HO-1 mRNA
induction.Wesuspect thatNOstimulation caused theproduction
of an unknown internal ligand(s) for MIF. SPR analysis revealed
that the BTZO-1-hMIF interaction required the intact N-terminal
Pro1. Pro1 and several residues around this site are invariant
among all known MIF homologs; Pro1 is nucleophilic due to its
location in a hydrophobic environment and has been reported
to interact with electrophiles and alkylating agents such as
NAPQI (Senter et al., 2002; Lolis and Bucala, 2003). The fact
that many ARE-activating agents are electrophiles (Nguyen4, December 22, 2010 ª2010 Elsevier Ltd All rights reserved 1291
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MIF Regulates ARE Activationet al., 2003b; Chen and Kunsch, 2004) raises the possibility that
the MIF N-terminal Pro1 domain functions as a receptor for dele-
terious electrophiles. Whether other ARE-activating agents func-
tion by binding to MIF is worthy of additional investigation.
The binding affinity of ISO-1, which typically binds to a deep
pocket near Pro-1 (Lubetsky et al., 2002), to the BTZO-1 binding
site in MIF was at least 1000 times less potent than BTZO-1,
whereas ISO-1 wasmore potent than BTZO-1 in inhibiting tauto-
merase activity. Moreover, ISO-1 was at least 30 times less
potent than BTZO-1 in ARE activation. Thus, we speculate that
BTZO-1 binds to a different site than ISO-1 in solution. The co-
crystallization study with BTZO-14 revealed two possible
BTZO-1 binding sites: the canonical MIF inhibitor binding site;
and a latent site at the interface area between adjacent
symmetry-related MIF molecules, which is nearly identical to
the reported cryptic ‘‘hydrophobic rim’’ binding site (McLean
et al., 2010) or the allosteric binding site (Cho et al., 2010).
Although the space groups and crystal packing of the crystals
from the previous studies were different from the crystals in
this work, the observed bindings are almost the same. Thus,
this latent binding site may not be a crystallization artifact. More-
over, this binding site can account for our enzyme and binding
assay results. Further studies are needed to clarify the precise
binding site of BTZO-1 in MIF.
The intracellular signaling pathway used by the BTZO-1-MIF
complex to activate ARE-mediated gene expression is not yet
clear. A decreased cytoplasmic MIF protein level (50%), but
not the MIF protein level in the medium (>70%), agrees well
with the reduced GST Ya mRNA level induced by 3 mM of
BTZO-1 (50%). Intracellular MIF may mediate the downstream
signaling pathway. The addition of 10 mM of rMIF was needed
to restore normal GST Ya mRNA induction caused by 3 mM of
BTZO-1 in MIF-reduced H9c2 cells (50% reduction). Under the
conditions used in Figure 2B, MIF levels in the medium and
in cells were 3.1 ng/ml and 0.021 pg/cell, respectively, and
BTZO-1 stimulation did not affect these MIF levels. If the
cell diameter is approximately 10 mm, the cellular MIF concentra-
tions would reach 1.7 mM. Thus, it is conceivable that a high
concentration of MIF was needed for cellular uptake by endocy-
tosis and to promote MIF-mediated ARE activation. In fact, 3 mM
of MIF was used to induce GST expression in cardiomyocytes
(Takahashi et al., 2001).
In conclusion, our results provide new models for both MIF
action and ARE activation; binding of BTZO-1 to MIF leads to
ARE activation. In inflammatory disease states, high levels of
MIF signaling potentially activating additional pathways might
be deleterious. However, our study suggests that MIF stimula-
tion by BTZO-1 could protect cells from oxidative insult in
some disease states. The discovery of a novel MIF stimulator
with such a previously unrecognized mechanism of action was
unexpected. Our studies further demonstrate that forward
chemical genetics can result in the efficient identification of
new drugs and new molecular targets (Kimura et al., 2010).
SIGNIFICANCE
Understanding cellular response to oxidative stress has
broad implications for human diseases. In a screening
program aimed at discovering therapeutic drugs for heart1292 Chemistry & Biology 17, 1282–1294, December 22, 2010 ª2010diseases, we identified BTZO-1, a 1,3-benzothiazin-4-one
derivative, which activated antioxidant response element
(ARE)-mediated gene expression and suppressed oxidative
stress-induced cardiomyocyte apoptosis in vitro. BTZO-2,
an active BTZO-1 derivative for ARE activation, protected
heart tissue during ischemia/reperfusion injury in rats. ARE
is a cis-acting DNA regulatory element involved in the induc-
tion of multiple cytoprotective factors, and its activation is
considered a mechanism of critical importance to cellular
protection against oxidative stress in mammalian cells.
BTZO-1 derivatives might offer a new class of drugs with
the potential for treating heart diseases. Macrophagemigra-
tion inhibitory factor (MIF), which is known to protect cells
from oxidative insult, was identified as a specific BTZO-1-
binding protein. BTZO-1 bound to MIF with a Kd of 68.6
nM, and its binding required the N-terminal Pro1. MIF, in
the presence of BTZO-1, activated the glutathione S-trans-
ferase Ya subunit (GST Ya) gene ARE, whereas reduction
of cellular MIF protein levels by siRNA suppressed BTZO-1-
induced GST Ya expression. MIF has been considered an
upstream regulator of innate and acquired immune res-
ponses. However, the ubiquitous expression of MIF implies
it has biological functions other than immune response.
Our results suggest that MIF activates the GST Ya gene
ARE in the presence of a ligand, with BTZO-1 the first
example of such a MIF ligand.
EXPERIMENTAL PROCEDURES
Isolation of Neonatal Rat Cardiomyocytes
Neonatal rat cardiomyocytes were prepared by proteinase digestion followed
by preplating to deplete the cell population of adherent nonmyocardial cells as
described previously with some modifications (Fujio et al., 1997).
All animal experiments including isolation of neonatal rat cardiomyocytes
were conducted under the guidelines of the Takeda Experimental Animal
Care and Use Committee.
Cell Survival Assays
Cell death was induced in cardiomyocytes by serum deprivation at low cell
density (3 3 105 cells/ml) for 4 days (Sheng et al., 1997), by DOX treatment
(Wang et al., 1998), or by NOR3 treatment. Cell viability was evaluated by
the WST-8 assay (Kimura et al., 2010).
ARE-Luc Reporter Assay
The rat GST Ya gene ARE (GAGCTTGGAAATGGCATTGCTAATGGTGA
CAAAGCAACTTTG) (Dhakshinamoorthy and Jaiswal, 2000) and mutant ARE
(GAGCTTGGAAATGGCATTGCTAATGGTGGCAAAGCAACTTTG) (Rushmore
et al., 1991) were subcloned into the pGL3 vector (Promega) to generate the
reporter plasmid pGL3-ARE-Luc and pGL3-mARE-Luc.
H9c2 cells transfected with pGL3-ARE-Luc or pGL3-mARE-Luc were stim-
ulated with BTZO-1 derivatives or 1 mM of BTZO-1 derivatives together with
rMIF for about 24 hr. Cell lysates were prepared using the Steady-Glo Lucif-
erase Assay System (Promega), and luciferase activity was measured with
the WALLAC ARVO SX (PerkinElmer, Inc.).
Evaluation of GST Ya and HO-1 Expression
To evaluate the effects of BTZO-1 derivatives on the induction of GST Ya and
HO-1 in cardiomyocytes, cells were stimulated with the indicated concentra-
tion of various samples or vehicle in Medium 199 (M-199) with 1% penicillin-
streptomycin solution (PS) for 24 hr.
To assess the effects of rMIF on GST Ya and HO-1 mRNA levels in cardio-
myocytes, cells were cultured with vehicle or the indicated concentration of
rMIF in the presence or absence of 10 mM NOR3 for 3 hr (HO-1) or 6 hr (GST
Ya) in M-199 with 1% PS.Elsevier Ltd All rights reserved
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were stimulated with the indicated concentration of rMIF and 3 mM of BTZO-1
derivatives in DMEM with 0.5% FBS for 6 hr (HO-1) or 24 hr (GST Ya).
Drug-Affinity Chromatography
BTZO-1 derivatives were coupled to AF-Amino TOYOPEARL (TOSOH Biosci-
ence GmbH) as previously described (Kimura et al., 2010). Binding buffer
(10 mM Tris-HCl[ pH 7.5], 20% glycerol, 1 mM EDTA, 100 mM NaCl, 0.5 mM
p-APMSF, 1 mM DTT) and elution buffer (10 mM Tris-HCl [pH 7.5], 20% glyc-
erol, 1 mM EDTA, 1 M NaCl, 0.5 mM p-APMSF, 1 mM DTT) were used.
SPR Analysis
Interactions of MIF with BTZO-12 or BTZO-13 were examined using the
BIACORE 3000 system (GE Healthcare UK Limited) at 25C. BTZO-12
and BTZO-13 were each immobilized on the activated sensor chip CM5
(BTZO-12-type chip, BTZO-13-type chip). Binding data were analyzed using
the BIACORE-3000 control software and the BIA evaluation software (GE
Healthcare UK Limited).
SPA
The SPAwas set up in 96-well LumiNunc plates (Thermo Fisher Scientific, Inc.)
using YSi (2–5 mm) copper His-tag SPA beads (GE Healthcare UK Limited),
[3H]-BTZO-1, and 6His-tagged hMIF or rMIF protein, and a microplate scintil-
lation counter (TopCount NXT; PerkinElmer, Inc.) was used for measurements.
RNA Interference
Small interference RNAs (siRNAs) for rMIF (50-GCUCAUGACUUUUAGUG
GC-30 ) and silencer negative control number 1 siRNA (4611) were obtained
from Life Technologies. H9c2 cells were transfected with either MIF siRNA
or control siRNA (100 nM) using Opti-MEM (Life Technologies) and Oligofect-
amine (Life Technologies).
Statistical Analysis
The effect of BTZO-2 on ischemia/reperfusion injury in rats was analyzed by
the Aspin-Welch test. In Figure 5, NO-induced cell death (Figure 5A) was
analyzed by the t test, GST Ya induction in the presence of NOR3 (Figure 5B),
and pGL3-ARE-Luc activation in the presence of BTZO-1 (Figure 5C) were
analyzed by the one-tailed Shirley-Williams test, and other experiments were
analyzed by the one-tailed Williams’s test. In Figure 6D, effects of MIF reduc-
tion on drug efficacy were examined by the Aspin-Welch test.
Detailed methods and other procedures are described in the Supplemental
Experimental Procedures.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and two tables, and can be found with this article online at
doi:10.1016/j.chembiol.2010.10.011.
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